Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
NurExone Biologic ( (TSE:NRX) ) has shared an update.
NurExone Biologic Inc. has announced promising preclinical results for its lead product, ExoPTEN, which demonstrated significant improvement in motor function recovery in a spinal cord injury model. The study showed that 100% of animals treated with a high dose of ExoPTEN regained walking ability, highlighting the drug’s potential therapeutic impact and paving the way for further studies and eventual clinical trials.
The most recent analyst rating on (TSE:NRX) stock is a Buy with a C$2.61 price target. To see the full list of analyst forecasts on NurExone Biologic stock, see the TSE:NRX Stock Forecast page.
More about NurExone Biologic
NurExone Biologic Inc. is a biotech company listed on the TSX Venture Exchange, OTCQB, and Frankfurt, focusing on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, targets acute spinal cord and optic nerve injuries, with significant preclinical data supporting its clinical potential in these multi-billion-dollar markets.
Average Trading Volume: 27,286
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$40.36M
Find detailed analytics on NRX stock on TipRanks’ Stock Analysis page.